Awakura Y, Yamamoto M, Fukuzawa S, Itoh N, Nonomura M, Fukuyama T
Department of Urology, Kyoto National Hospital.
Hinyokika Kiyo. 2000 Jul;46(7):449-52.
We evaluated the efficacy of the combination of estramustine phosphate and vinblastine in 13 patients with hormone-refractory prostate cancer. Of 12 patients with an elevated prostate specific antigen (PSA) level at the start of treatment, 5 (42%) had a greater than 50% decrease in PSA level. In a patient with cervical and mediastinal lymph node metastases, about a 57% decrease was observed in bidimensional measurement. Side effects were mild and manageable. The survival rate was not significantly different between patients who showed a greater than 50% decrease in PSA levels or regression of lymph node metastases versus the other patients.
我们评估了磷酸雌莫司汀和长春碱联合用药对13例激素难治性前列腺癌患者的疗效。在治疗开始时前列腺特异性抗原（PSA）水平升高的12例患者中，5例（42%）的PSA水平下降超过50%。在一名有颈部和纵隔淋巴结转移的患者中，二维测量显示约有57%的缩小。副作用轻微且可控。PSA水平下降超过50%或淋巴结转移消退的患者与其他患者的生存率没有显著差异。
